Overexpression of HER2/neu and epidermal growth factor receptor in node-negative T1-3 breast cancer: An appraisal of the prognostic value and their impact on the selection of patients for systemic adjuvant therapy

Growth Factor ◽

Prognostic Value ◽

Growth Factor Receptor ◽

Node Negative ◽

Systemic Adjuvant Therapy ◽

Epidermal Growth ◽

Selection Of Patients ◽

Selection Of

Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer

Cancer ◽

10.1002/cncr.26647 ◽

2011 ◽

Vol 118 (13) ◽

pp. 3236-3243 ◽

Cited By ~ 30

Author(s):

Lorenzo Livi ◽

Icro Meattini ◽

Calogero Saieva ◽

Ciro Franzese ◽

Vanessa Di Cataldo ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Growth Factor ◽

Prognostic Value ◽

Growth Factor Receptor ◽

Node Negative ◽

Node Negative Breast Cancer ◽

Hormone Status ◽

Prognostic Value of Estrogen and Progesterone Receptor Expression in Low Proliferative Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Journal of Breast Disease ◽

10.14449/jbd.2017.5.2.64 ◽

2017 ◽

Vol 5 (2) ◽

pp. 64-70

Author(s):

Yujin Lee ◽

Inseok Park ◽

Hyunjin Cho ◽

Keunho Yang ◽

Jungbin Kim ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen And Progesterone Receptor

Growth Factor ◽

Epidermal Growth Factor ◽

Prognostic Value ◽

Growth Factor Receptor ◽

Receptor Expression ◽

Progesterone Receptor Expression ◽

Epidermal Growth ◽

Combination Trastuzumab and Chemotherapy May Have a Role in Women With Small, Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2014.58.2965 ◽

2015 ◽

Vol 33 (1) ◽

pp. 124-125 ◽

Cited By ~ 1

Author(s):

Heather L. McArthur ◽

Patrick G. Morris ◽

Clifford A. Hudis

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Node Negative ◽

Human Epidermal Growth Factor ◽

Epidermal Growth ◽

Abstract PS10-52: Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

10.1158/1538-7445.sabcs20-ps10-52 ◽

2021 ◽

Author(s):

Omer Diker ◽

Burak Yasin Aktas ◽

Recep Ak ◽

Bahadir Koylu ◽

Onur Bas ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Life Experience ◽

Real Life ◽

Growth Factor Receptor ◽

Node Negative ◽

Epidermal Growth ◽

Prognostic value of epidermal growth factor receptor (EGFR) family members in breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.e21079 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e21079-e21079

Author(s):

T. Badovinac Crnjevic ◽

J. Jakic-Razumovic ◽

D. Vrbanec ◽

A. Juretic ◽

S. Plestina ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Prognostic Value ◽

Family Members ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Egfr Family

Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor

Molecular and Clinical Oncology ◽

10.3892/mco.2016.776 ◽

2016 ◽

Vol 4 (4) ◽

pp. 648-654 ◽

Cited By ~ 11

Author(s):

MASAHIRO OHARA ◽

KAZUO MATSUURA ◽

ETSUSHI AKIMOTO ◽

MIDORI NOMA ◽

MIHOKO DOI ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Prognostic Value ◽

Growth Factor Receptor ◽

Ki67 Labeling Index ◽

Estrogen Receptor Positive ◽

Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer

Surgery ◽

10.1067/msy.2003.32 ◽

2003 ◽

Vol 133 (2) ◽

pp. 219-221 ◽

Cited By ~ 33

Author(s):

Shinichi Tsutsui ◽

Shinji Ohno ◽

Shigeru Murakami ◽

Akemi Kataoka ◽

Junko Kinoshita ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Prognostic Value ◽

Growth Factor Receptor ◽

Epidermal growth factor receptor and S-phase fraction as prognosticator combination in node negative primary breast cancer

The Breast ◽

10.1016/0960-9776(93)90005-z ◽

1993 ◽

Vol 2 (4) ◽

pp. 229-233 ◽

Cited By ~ 3

Author(s):

G.v. Minckwitz ◽

M. Kaufmann ◽

H. Schmid ◽

K. Goerttler ◽

G. Bastert

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Primary Breast Cancer ◽

Growth Factor Receptor ◽

S Phase ◽

Phase Fraction ◽

Node Negative ◽

Faculty Opinions recommendation of Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735447541.793581150 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Node Negative ◽

Human Epidermal Growth Factor ◽

Epidermal Growth ◽

Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Escalation or De-Escalation?

Journal of Clinical Oncology ◽

10.1200/jco.21.01716 ◽

2021 ◽

pp. JCO.21.01716

Author(s):

Maho Tanaka ◽

Akihiko Shimomura ◽

Hiroyuki Terakado ◽

Chikako Shimizu

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Adjuvant Treatment ◽

Growth Factor Receptor ◽

Node Negative ◽

Human Epidermal Growth Factor ◽

Epidermal Growth ◽